{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:52Z","timestamp":1792425352321,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00296-016-3575-3","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T03:38:14Z","timestamp":1475465894000},"page":"1719-1725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Yesim","family":"Ozguler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Borekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersan","family":"Atahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Ongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"issue":"3","key":"3575_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000434684","volume":"90","author":"S Borekci","year":"2015","unstructured":"Borekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G (2015) Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment. Respiration 90(3):191\u2013198. doi: 10.1159\/000434684","journal-title":"Respiration"},{"issue":"Suppl 3","key":"3575_CR2","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1086\/429994","volume":"41","author":"HM Algood","year":"2005","unstructured":"Algood HM, Lin PL, Flynn JL (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41(Suppl 3):S189\u2013S193. doi: 10.1086\/429994","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3575_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ G\u00f3mez-Reino","year":"2007","unstructured":"G\u00f3mez-Reino JJ, Carmona L, \u00c1ngel Descalzo M (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756\u2013761. doi: 10.1002\/art.22768","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3575_CR4","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","volume":"34","author":"MK Nisar","year":"2015","unstructured":"Nisar MK, Rafiq A, Ostor AJ (2015) Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clin Rheumatol 34(12):2141\u20132145. doi: 10.1007\/s10067-015-3099-3","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3575_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care C","year":"2005","unstructured":"British Thoracic Society Standards of Care C (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60(10):800\u2013805. doi: 10.1136\/thx.2005.046797","journal-title":"Thorax"},{"issue":"8","key":"3575_CR6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62(8):791","journal-title":"Ann Rheum Dis"},{"key":"3575_CR7","unstructured":"World Health Organization. Global tuberculosis report (2015). www.who.int\/tb\/publications\/global_report\/en . Accessed Nov 4 2015"},{"key":"3575_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3899\/jrheum.140106","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Prignano F, Goletti D (2014) Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl 91:78\u201382. doi: 10.3899\/jrheum.140106","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"3575_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","volume":"14","author":"B Denis","year":"2008","unstructured":"Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, Salmon D, Mariette X, Lortholary O, Group R (2008) Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 14(2):183\u2013186. doi: 10.1111\/j.1469-0691.2007.01891.x","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3575_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/art.23210","volume":"58","author":"S Aslanidis","year":"2008","unstructured":"Aslanidis S, Pyrpasopoulou A, Douma S, Petidis K (2008) Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 58(1):327\u2013328. doi: 10.1002\/art.23210","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3575_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/rheumatology\/keu041","volume":"53","author":"YJ Kim","year":"2014","unstructured":"Kim YJ, Kim YG, Shim TS, Koo BS, Hong S, Lee CK, Yoo B (2014) Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology 53(8):1477\u20131481. doi: 10.1093\/rheumatology\/keu041","journal-title":"Rheumatology"},{"issue":"4","key":"3575_CR12","doi-asserted-by":"crossref","first-page":"e0153816","DOI":"10.1371\/journal.pone.0153816","volume":"11","author":"HW Kim","year":"2016","unstructured":"Kim HW, Kwon SR, Jung K-H, Kim S-K, Baek HJ, Seo MR et al (2016) Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean society of spondyloarthritis research. PLoS One 11(4):e0153816","journal-title":"PLoS One"},{"issue":"1","key":"3575_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3346\/jkms.2014.29.1.38","volume":"29","author":"YS Suh","year":"2014","unstructured":"Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH (2014) Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy. J Korean Med Sci 29(1):38\u201342. doi: 10.3346\/jkms.2014.29.1.38","journal-title":"J Korean Med Sci"},{"issue":"3","key":"3575_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.150177","volume":"43","author":"B Kisacik","year":"2016","unstructured":"Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A (2016) Characteristics predicting tuberculosis Risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43(3):524\u2013529. doi: 10.3899\/jrheum.150177","journal-title":"J Rheumatol"},{"issue":"7","key":"3575_CR15","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies G (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 60(7):1884\u20131894. doi: 10.1002\/art.24632","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3575_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.24476","volume":"61","author":"P Brassard","year":"2009","unstructured":"Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S (2009) Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 61(3):300\u2013304. doi: 10.1002\/art.24476","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3575_CR17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0007-0971(88)90073-3","volume":"82","author":"J Efthimiou","year":"1988","unstructured":"Efthimiou J, Hay PE, Spiro SG, Lane DJ (1988) Pulmonary tuberculosis in Behcet\u2019s syndrome. Br J Dis Chest 82(3):300\u2013304","journal-title":"Br J Dis Chest"},{"issue":"6","key":"3575_CR18","first-page":"692","volume":"12","author":"PC Coelho","year":"1994","unstructured":"Coelho PC, da Silva JA, Romeu JC, da Costa JC, de Queiroz MV (1994) Simultaneous appearance of Behcet\u2019s disease and pulmonary tuberculosis. Clin Exp Rheumatol 12(6):692","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-016-3575-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-016-3575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:13:08Z","timestamp":1498335188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-016-3575-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3575"],"URL":"https:\/\/doi.org\/10.1007\/s00296-016-3575-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]}}}